期刊
CANCER CELL
卷 12, 期 2, 页码 115-130出版社
CELL PRESS
DOI: 10.1016/j.ccr.2007.07.004
关键词
-
资金
- Intramural NIH HHS [Z01 SC004024-20] Funding Source: Medline
- NCI NIH HHS [CA55819, P01 CA055819] Funding Source: Medline
Mechanisms of constitutive NF-kappa B signaling in multiple myeloma are unknown. An inhibitor of I kappa B kinase beta(IKK beta) targeting the classical NF-kappa B pathway was lethal to many myeloma cell lines. Several cell lines had elevated expression of NIK due to genomic alterations or protein stabilization, while others had inactivating mutations of TRAF3; both kinds of abnormality triggered the classical and alternative NF-kappa B pathways. A majority of primary myeloma patient samples and cell lines had elevated NF-kappa B target gene expression, often associated with genetic or epigenetic alteration of NIK, TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, or NFKB2. These data demonstrate that addiction to the NF-kappa B pathway is frequent in myeloma and suggest that IKK beta inhibitors hold promise for the treatment of this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据